URGN UroGen Pharma Ltd.companySEC Filings & Insider Trading Activity 2026
Latest UroGen Pharma Ltd. (URGN) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 2, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on March 2, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for UroGen Pharma Ltd. (URGN) (SEC CIK 1668243), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.03: Creation of a Direct Financial Obligation
- • Item 2.03 signals a new financial obligation (loan, credit facility, or guarantee) that increases UroGen's debt load or contingent liabilities
- • No terms disclosed in provided text — full details likely in an accompanying exhibit or cross-referenced section
Item 1.01: Entry into a Material Definitive Agreement
- • Filing signed March 2, 2026 by CFO Chris Degnan, confirming authorized execution of material agreement disclosure
- • No deal terms, counterparty, or financial obligations disclosed in this section — full agreement details likely in attached exhibit
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results announced March 2, 2026
- • Full results detail contained in Exhibit 99.1 press release — primary source for revenue, earnings, and guidance figures
Recent 8-K FilingsCurrent Reports
AI-powered analysis of UroGen Pharma Ltd. (URGN) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 2, 2026 | — | Analysis | — |
8-K | Mar 2, 2026 | — | Analysis | — |
10-K | Mar 2, 2026 | Dec 31, 2025 | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 12, 2025 | Mar 31, 2025 | — | |
10-K | Mar 10, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 13, 2024 | Jun 30, 2024 | — | |
10-Q | May 13, 2024 | Mar 31, 2024 | — | |
10-K | Mar 14, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 14, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 10, 2023 | Jun 30, 2023 | — | |
10-Q | May 11, 2023 | Mar 31, 2023 | — | |
10-K | Mar 24, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 10, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 11, 2022 | Jun 30, 2022 | — | |
10-Q | May 10, 2022 | Mar 31, 2022 | — | |
10-K | Mar 21, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 15, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 4, 2021 | Jun 30, 2021 | — | |
10-Q | May 13, 2021 | Mar 31, 2021 | — | |
10-K | Mar 18, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 9, 2020 | Sep 30, 2020 | — | |
10-Q | Aug 10, 2020 | Jun 30, 2020 | — |
Frequently Asked Questions
What are the latest URGN SEC filings in 2026?
UroGen Pharma Ltd. (URGN) has filed a 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on March 2, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did URGN file its most recent 10-K annual report?
UroGen Pharma Ltd. (URGN) filed its most recent 10-K annual report on March 2, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view URGN 10-Q quarterly reports?
UroGen Pharma Ltd. (URGN)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every URGN 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has URGN filed recently?
UroGen Pharma Ltd. (URGN)'s most recent 8-K was filed on March 2, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find URGN insider trading activity (Form 4)?
SignalX aggregates every URGN Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does URGN file with the SEC?
UroGen Pharma Ltd. (URGN) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new URGN filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for UroGen Pharma Ltd. (URGN).
What is URGN's SEC CIK number?
UroGen Pharma Ltd. (URGN)'s SEC CIK (Central Index Key) number is 1668243. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1668243 to look up all URGN filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find URGN return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from UroGen Pharma Ltd. (URGN) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of UroGen Pharma Ltd. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 32+ filings.